King's College Hospital, Denmark Hill, London, UK.
Clin Exp Ophthalmol. 2011 Jan;39(1):5-8. doi: 10.1111/j.1442-9071.2010.02424.x. Epub 2010 Dec 16.
Ranibizumab (Lucentis, Novartis, Basel, Switzerland) is currently indicated for use in neovascular age-related macular degeneration (NVAMD). This study assessed the real-life outcomes based on baseline visual acuity when treated with intravitreal ranibizumab on a three + pro re nata (PRN) dosing schedule for NVAMD.
This retrospective chart-review was conducted at King's College Hospital. The patients were stratified into three groups based on baseline Early treatment diabetic retinopathy study (ETDRS) letters: 27 with poor visual acuity (24-34 letters), 33 with intermediate visual acuity (35-54 letters) and 27 with good visual acuity (≥=55 letters).
All patients received a three + PRN dosing schedule of ranibizumab injections (0.5 mg per 0.05 mL) based on changes in visual acuity and macular thickness on optical coherence tomography (OCT) and all patients completed 12-month follow up.
The mean change in visual acuity at 12 months in the three groups.
Mean gain in ETDRS letters at 12 months was +14.00 (P < 0.0001), +7.10 (P = 0.012) and +2.85 (P = 0.19), and mean number of injections was 5.30, 6.12 and 5.70 in the poor, intermediate and good baseline vision group, respectively, over the 12- month follow-up period.
Poor baseline visual acuity (24-34 ETDRS letters) is a predictor of maximum gain in visual acuity. However, eyes with better baseline visual acuity (55 letters) had a better final visual acuity.
雷珠单抗（罗氏，巴塞尔，瑞士）目前被批准用于新生血管性年龄相关性黄斑变性（NVAMD）的治疗。本研究评估了基于基线视力的真实临床疗效，对 NVAMD 患者采用玻璃体腔注射雷珠单抗，每 3 个月按需（PRN）治疗方案。
这是一项在国王学院医院进行的回顾性图表研究。根据基线视力，将患者分为三组：视力差（24-34 个字母）组 27 例，视力中等（35-54 个字母）组 33 例，视力好（≥55 个字母）组 27 例。
所有患者均采用玻璃体腔注射雷珠单抗（0.5mg/0.05ml），根据视力和光学相干断层扫描（OCT）上黄斑厚度的变化，按 3+PRN 方案治疗，所有患者均完成 12 个月随访。
三组患者在 12 个月时视力的平均变化。
12 个月时，平均视力提高（ETDRS 字母）分别为+14.00（P<0.0001）、+7.10（P=0.012）和+2.85（P=0.19），在 12 个月的随访中，视力差（24-34 个字母）、中等（35-54 个字母）和视力好（≥55 个字母）的患者的平均注射次数分别为 5.30、6.12 和 5.70。
基线视力差（24-34 ETDRS 字母）是视力提高最大的预测指标。然而，基线视力较好（55 个字母）的患者最终视力更好。
